Location: Solmed Polyclinic (Zagreb)
Study Drug: Experimental biological therapy that blocks the effect of the pro-inflammatory molecule TL1A.
Main Inclusion Criteria: Patients over 18 years of age with an official diagnosis of Crohn’s disease who, with at least one previous line of treatment (either conventional or biological therapy), have symptoms of active disease.
Status: In preparation
Start of patient enrollment: September 2024.